Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.02 USD | -0.42% | -0.22% | +63.71% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.71% | 2.64B | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.29% | 22.28B | |
-5.57% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- SVB Securities Adjusts Merus' Price Target to $39 from $33, Keeps Outperform Rating